2019
Immune reaction by cytoreductive prostatectomy.
Lee G, Srivastava A, Kwon Y, Kim I. Immune reaction by cytoreductive prostatectomy. American Journal Of Clinical And Experimental Urology 2019, 7: 64-79. PMID: 31139701, PMCID: PMC6526355.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerCytoreductive prostatectomyProstate cancerMetastatic diseaseCastration-resistant prostate cancerCommon non-cutaneous cancerCastration-resistant diseaseResistant prostate cancerMale cancer deathsNon-cutaneous cancerNovel treatment strategiesImmunologic changesAdvanced diseaseOncologic outcomesSurvival benefitCombinational immunotherapyCancer deathTreatment modalitiesHormonal manipulationMetastatic cancerTreatment strategiesImmune reactionsSurvival rateEffective cureCancer
2016
Chapter 57 Second-Line Hormonal for Castrate-Resistant Prostate Cancer
Parihar J, Kim I. Chapter 57 Second-Line Hormonal for Castrate-Resistant Prostate Cancer. 2016, 533-540. DOI: 10.1016/b978-0-12-800077-9.00057-8.Peer-Reviewed Original ResearchCastrate-resistant prostate cancerProstate cancerHormonal manipulationHormone-sensitive prostate cancerSecond-line hormonal manipulationsSecond-line hormonal therapySecond-line treatment optionAssociated response ratesInitial systemic therapySecondary hormonal manipulationsSecond-generation antiandrogensFirst-generation antiandrogensAntiandrogen withdrawalARN-509Hormonal therapyMainstay treatmentAbiraterone acetateAndrogen suppressionSystemic therapyAndrogen deprivationSuch patientsTreatment optionsTherapeutic responseDisease progressionResponse rate